Automation of up to 564 samples in a day.
With “pooled sampling” the system can test 2,820 samples per day.
December 6th, 2021 - Applied BioCode SARS-CoV-2 Test Detects Omicron and Other COVID Variants More...
December 10th, 2020 - Applied BioCode Receives Emergency Use Authorization for Pooled COVID-19 Testing. More...
June 16th, 2020 - BioCode® SARS CoV-2 Assay Now authorized by the FDA under the Emergency Use Authorization (EUA). More...
瑞磁生技's BioCode® SARS-CoV-2 Assay is a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs. The BioCode® SARS-CoV-2 runs on the automated BioCode® MDx-3000 high throughput molecular diagnostic system and can deliver up to 188 sample results in an 8 hour shift (564 samples in a day).
The BioCode® SARS-CoV-2 Assay provides sensitive and reliable results detecting the two major viral genes to the SARS-CoV-2 virus that are recommended by the US Centers for Disease Control (CDC). (N1 gene, N2 gene) The BioCode® SARS-CoV-2 Assay can be run as a single assay or paired with our BioCode® Respiratory Pathogen Panel to provide a more complete respiratory profile of your patients.
The BioCode® MDx-3000 system offers the high volume laboratory an alternative to high cost, single use, cartridge based molecular test systems. The BioCode® MDx-3000 system has the ability to process up to 3 different multiplex panels on the same run. The user-friendly automated system also offers target masking capabilities within panels to address variation in physician test ordering patterns and potential changes in panel reimbursement.
更多資訊：
瑞磁生技 - 數位條碼檢測新冠病毒
如何訂購:
欲瞭解產品技術資訊，或討論相關研究試驗:
請電 +886-2-8791-6833
或來信至陳祐寧先生
ychen@apbiocode.com
| Product Number | Product Name |
|---|---|
| 41-A0051 | BioCode® MDx-3000 System |
| 64-C0304 | BioCode® SARS-CoV-2 Assay Kit - 96 Well Test Kit |
| 63-R0001 | BioCode® Respiratory Pathogen Panel - 96 Well Test Kit |